Aberrant and alternative splicing in skeletal system disease

Gene

Volumn 528, Issue 1, 2013, Pages 21-26

  Fan, Xin ^a   Tang, Liling ^a  

^a CHONGQING UNIVERSITY   (China)

Author keywords

Biomarker; Mutation; Skeletal system disease; Splice site; Splicing

Indexed keywords

B7 ANTIGEN; COLLAGEN TYPE 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBRONECTIN; HERMES ANTIGEN; INTERLEUKIN 32; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; MITOGEN ACTIVATED PROTEIN KINASE 1; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; TIE 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCOUPLING PROTEIN 2; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ABERRANT SPLICING; ALTERNATIVE RNA SPLICING; BINDING SITE; BONE DISEASE; BONE NECROSIS; CHONDROSARCOMA; CODON; EWING SARCOMA; EXON; GENE MUTATION; HUMAN; NONHUMAN; NORRIE DISEASE; NUCLEIC ACID BASE SUBSTITUTION; OPEN READING FRAME; OSTEOARTHRITIS; OSTEOPOROSIS; OSTEOPOROSIS PSEUDOGLIOMA SYNDROME; OSTEOSARCOMA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RNA SPLICING; SPONDYLOEPIPHYSEAL DYSPLASIA;

ALPHA 1 TYPE I COLLAGEN; BIOMARKER; CD44; CLUSTER OF DIFFERENTIATION 44; COL1A1; EDA; EXTRA DOMAIN A; FGFR3; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST-LIKE SYNOVIOCYTES; FIBRONECTIN; FLS; FN; LIPOPROTEIN RECEPTOR-RELATED PROTEIN 5; LRP5; MESENCHYMAL STEM CELLS; MSC; MUTATION; OI; OPS; OSTEOGENESIS IMPERFECT; OSTEOPOROSIS-PSEUDOGLIOMA SYNDROME; RA; RHEUMATOID ARTHRITIS; SEDL OR SEDT; SKELETAL SYSTEM DISEASE; SPLICE SITE; SPLICING; SPONDYLOEPIPHYSEAL DYSPLASIA TARDA; TRAFFICKING PROTEIN PARTICLE COMPLEX 2; TRAPPC2; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF OR VEGF-A; VEGF RECEPTOR; VEGFR;

ALTERNATIVE SPLICING; BONE DISEASES; COLLAGEN TYPE I; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-5; MEMBRANE TRANSPORT PROTEINS; MUTATION; PROTEIN ISOFORMS; RNA PRECURSORS; RNA SPLICE SITES; TRANSCRIPTION FACTORS;

EID: 84882605890     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.06.027     Document Type: Review

References (54)

1. Ai M.R., Heeger S., Bartels C.F., Schelling D.K. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. Am. J. Hum. Genet. 2005, 77:741-753. Osteoporosis-Pseudoglioma Collaborat, G.
2. Barbirato C., et al. A novel COL1A1 gene-splicing mutation (c. 1875+1G>C) in a Brazilian patient with osteogenesis imperfecta. Genet. Mol. Res. 2009, 8:173-178.
3. Canete J.D., et al. Clinical significance of high levels of soluble tumour necrosis factor-alpha receptor-2 produced by alternative splicing in rheumatoid arthritis: a longitudinal prospective cohort study. Rheumatology 2011, 50:721-728.
4. Chang H.-H., et al. PTPN22.6, a dominant negative isoform of PTPN22 and potential biomarker of rheumatoid arthritis. PLoS One 2012, 7. (e33067-e33067).
5. Chevalier X., Claudepierre P., Groult N., Zardi L., Hornebeck W. Presence of ED-A containing fibronectin in human articular cartilage from patients with osteoarthritis and rheumatoid arthritis. J. Rheumatol. 1996, 23:1022-1030.
6. Faustino N.A., Cooper T.A. Pre-mRNA splicing and human disease. Genes Dev. 2003, 17:419-437.
7. Ffrench-Constant C. Alternative splicing of fibronectin - many different proteins but few different functions. Exp. Cell Res. 1995, 221:261-271.
8. Gedeon A.K., et al. The molecular basis of X-linked spondyloepiphyseal dysplasia tarda. Am. J. Hum. Genet. 2001, 68:1386-1397.
9. Grisar J., et al. Expression patterns of CD44 and CD44 splice variants in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 2012, 30:64-72.
10. Guo H., et al. A novel RNA-splicing mutation in TRAPPC2 gene causing X-linked spondyloepiphyseal dysplasia tarda in a large Chinese family. J. Genet. 2009, 88:87-91.
11. Hasegawa M., et al. Expression of large tenascin-C splice variants in synovial fluid of patients with rheumatoid arthritis. J. Orthop. Res. 2007, 25:563-568.
12. Heinhuis B., Koenders M.I., van de Loo F.A., Netea M.G., van den Berg W.B., Joosten L.A.B. Inflammation-dependent secretion and splicing of IL-32 gamma in rheumatoid arthritis. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:4962-4967.
13. Huang G.X., Zhou Z.C., Wang H., Kleinerman E.S. CAPER-α alternative splicing regulates the expression of vascular endothelial growth factor165 in Ewing sarcoma cells. Cancer 2012, 118:2106-2116.
14. Jang J.-H. Identification and characterization of soluble isoform of fibroblast growth factor receptor 3 in human SaOS-2 osteosarcoma cells. Biochem. Biophys. Res. Commun. 2002, 292:378-382.
15. Jang J.-H., Chung C.-P. Loss of ligand-binding specificity of fibroblast growth factor receptor 2 by RNA splicing in human chondrosarcoma cells. Cancer Lett. 2003, 191:215-222.
16. Jin P., et al. Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis. Arthritis Res. Ther. 2008, 10.
17. Kilian O., et al. Expression of EDA+ and EDB+ fibronectin splice variants in bone. Bone 2004, 35:1334-1345.
18. Kim H.S., Park Y.B., Oh J.H., Jeong J., Kim C.J., Lee S.H. Expression of CD44 isoforms correlates with the metastatic potential of osteosarcoma. Clin. Orthop. Relat. Res. 2002, 184-190.
19. Kuryu M., Ozaki T., Nishida K., Shibahara M., Kawai A., Inoue H. Expression of CD44 variants in osteosarcoma. J. Cancer Res. Clin. Oncol. 1999, 125:646-652.
20. Ladd A.N., Cooper T.A. Finding signals that regulate alternative splicing in the post-genomic era. Genome Biol. 2002, 3. (reviews0008).
21. Laine C.M., et al. Novel mutations affecting LRP5 splicing in patients with osteoporosis-pseudoglioma syndrome (OPPG). Eur. J. Hum. Genet. 2011, 19:875-881.
22. Marini J.C., et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum. Mutat. 2007, 28:209-221.
23. Matsui Y., et al. Alternative splicing of fibronectin transcripts in osteochondrogenic tumors. Anticancer. Res. 2001, 21:1103-1106.
24. Nagamori M., et al. In vivo immunogenicity of osteosarcoma cells that express B7-1a, an alternatively spliced form of B7-1. Anticancer. Res. 2002, 22:2009-2013.
25. Naor D., Nedvetzki S. CD44 in rheumatoid arthritis. Arthritis Res. Ther. 2003, 5:105-115.
26. Narumi S., et al. Various types of LRP5 mutations in four patients with osteoporosis-pseudoglioma syndrome: identification of a 7.2-kb microdeletion using oligonucleotide tiling microarray. Am. J. Med. Genet. A 2010, 152A:133-140.
27. Parker W.L., Finnson K.W., Soe-Lin H., Knaus P., Philip A. Expression and function of TβRII-B, a variant of the type II TGF-β receptor, in human chondrocytes. Osteoarthr. Cartil. 2007, 15:442-453.
28. Patil A.S., Sable R.B., Kothari R.M. Occurrence, biochemical profile of vascular endothelial growth factor (VEGF) isoforms and their functions in endochondral ossification. J. Cell. Physiol. 2012, 227:1298-1308.
29. Peng H., et al. A novel splicing mutation in COL1A1 gene caused type I osteogenesis imperfecta in a Chinese family. Gene 2012, 502:168-171.
30. Perbal B., et al. Prognostic relevance of CCN3 in Ewing sarcoma. Hum. Pathol. 2009, 40:1479-1486.
31. Perinpanayagam H., Schneider G., Holtman K., Zaharias R., Stanford C. Altered Cbfa1 expression and biomineralization in an osteosarcoma cell line. J. Orthop. Res. 2004, 22:404-410.
32. Pollitt R., et al. Mutation analysis of COL1A1 and COL1A2 in patients diagnosed with osteogenesis imperfecta type I-IV. Hum. Mutat. 2006, 27. 716-716.
33. Przybysz M., Borysewicz K., Katnik-Prastowska I. Differences between the early and advanced stages of rheumatoid arthritis in the expression of EDA-containing fibronectin. Rheumatol. Int. 2009, 29:1397-1401.
34. Pufe T., Petersen W., Tillmann B., Mentlein R. The angiogenic peptide vascular endothelial growth factor is expressed in foetal and ruptured tendons. Virchows Arch. 2001, 439:579-585.
35. Pufe T., Petersen W., Tillmann B., Mentlein R. Splice variants VEGF121 and VEGF165 of the angiogenic peptide vascular endothelial cell growth factor are expressed in the synovial tissue of patients with rheumatoid arthritis. J. Rheumatol. 2001, 28:1482-1485.
36. Pufe T., Petersen W., Tillmann B., Mentlein R. The splice variants VEGF(121) and VEGF(189) of the angiogenic peptide vascular endothelial growth factor are expressed in osteoarthritic cartilage. Arthritis Rheum. 2001, 44:1082-1088.
37. Pufe T., Wildermann B., Petersen W., Mentlein R., Raschke M., Schmidmaier G. Quantitative measurement of the splice variants 120 and 164 of the angiogenic peptide vascular endothelial growth factor in the time flow of fracture healing: a study in the rat. Cell Tissue Res. 2002, 309:387-392.
38. Rauch F., Glorieux F.H. Osteogenesis imperfecta. Lancet 2004, 363:1377-1385.
39. Rimoin D.L., Cohn D., Krakow D., Wilcox W., Lachman R.S., Alanay Y. The skeletal dysplasias: clinical-molecular correlations. Skeletal Biology and Medicine, Pt B: Disease Mechanisms and Therapeutic Challenges 2007, 302-309. M. Zaidi (Ed.).
40. Rousseau F., et al. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 1994, 371:252-254.
41. Ryder L.R., et al. FoxP3 mRNA splice forms in synovial CD4+ T cells in rheumatoid arthritis and psoriatic arthritis. APMIS 2012, 120:387-396.
42. Shaw M.A., et al. Identification of three novel SEDL mutations, including mutation in the rare, non-canonical splice site of exon 4. Clin. Genet. 2003, 64:235-242.
43. Shchetynsky K., Ronninger M., Padyukov L. Expression of alternatively spliced variants of MAP2K4 gene in rheumatoid arthritis. Ann. Rheum. Dis. 2012, 71:A59.
44. Shiang R., et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 1994, 78:335-342.
45. Shinde A.V., et al. Identification of the peptide sequences within the EIIIA (EDA) segment of fibronectin that mediate integrin alpha 9 beta 1-dependent cellular activities. J. Biol. Chem. 2008, 283:2858-2870.
46. Shiozawa K., Hino K., Shiozawa S. Alternatively spliced EDA-containing fibronectin in synovial fluid as a predictor of rheumatoid joint destruction. Rheumatology 2001, 40:739-742.
47. Srebrow A., Kornblihtt A.R. The connection between splicing and cancer. J. Cell Sci. 2006, 119:2635-2641.
48. Srivastava A., Rock C., Zhang K., Ruan M., Bolander M.E., Sarkar G. Expression of a novel alternatively spliced UCP-2 transcript in osteogenic sarcoma. J. Orthop. Sci. 2006, 11:51-57.
49. Varoga D., Drescher W., Pufe M., Groth G., Pufe T. Differential expression of vascular endothelial growth factor in glucocorticoid-related osteonecrosis of the femoral head. Clin. Orthop. Relat. Res. 2009, 467:3273-3282.
50. Venables J.P. Aberrant and alternative splicing in cancer. Cancer Res. 2004, 64:7647-7654.
51. Weber G.F., Bronson R.T., Ilagan J., Cantor H., Schmits R., Mak T.W. Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res. 2002, 62:2281-2286.
52. Wibulswas A., et al. Influence of epitopes CD44v3 and CD44v6 in the invasive behavior of fibroblast-like synoviocytes derived from rheumatoid arthritic joints. Arthritis Rheum. 2002, 46:2059-2064.
53. Xia X.-Y., et al. A novel insertion mutation in the SEDL gene results in X-linked spondyloepiphyseal dysplasia tarda in a large Chinese pedigree. Clin. Chim. Acta 2009, 410:39-42.
54. Xiong F., et al. Noncanonical and canonical splice sites: a novel mutation at the rare noncanonical splice-donor cut site (IVS4+1A>G) of SEDL causes variable splicing isoforms in X-linked spondyloepiphyseal dysplasia tarda. Eur. J. Hum. Genet. 2009, 17:510-516.